Monthly Archives: December 2021

Illuminating the brain: an interview with Karl Deisseroth Posted on December 31, 2021 by admin

Neurophotonics associate editor Dr. Yeka Aponte interviewed Dr. Karl Deisseroth, professor of psychiatry and behavioral sciences and of bioengineering at Stanford University School of Medicine. Readers are also invited to view the interview in video format: https://bcove.video/3nRfJ5g Aponte Y. Illuminating … Continue reading →

Posted in Uncategorized | Comments Off on Illuminating the brain: an interview with Karl Deisseroth
Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination Posted on December 29, 2021 by admin

“This cohort study found that full vaccination was associated with reduced risk of COVID-19 breakthrough infection, regardless of the immune status of patients. Despite full vaccination, persons with immune dysfunction had substantially higher risk for COVID-19 breakthrough infection than those … Continue reading →

Posted in Uncategorized | Comments Off on Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection Posted on December 17, 2021 by admin

https://www.nature.com/articles/s41591-021-01630-0

Posted in Uncategorized | Comments Off on Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection
Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects Posted on December 8, 2021 by admin

Abstract: Allosteric modulation represents an important approach in drug discovery because of its advantages in safety and selectivity. SOMCL-668 is the first selective and potent sigma-1 receptor allosteric modulator, discovered in our laboratory. The present work investigates the potential therapeutic … Continue reading →

Posted in Uncategorized | Comments Off on Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence Posted on December 3, 2021 by admin

Abstract:  “SARS-CoV-2 infection causes COVID-19, which frequently leads to clinical deterioration and/or long-lasting morbidity. Academic and governmental experts throughout the USA met in 2021 to discuss the potential for use of fluvoxamine as early treatment of SARS-CoV-2 infection. Fluvoxamine is … Continue reading →

Posted in Uncategorized | Comments Off on Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence